David spoke on "Cross-Border Business Considerations in a Hatch-Waxman Scenario,"
Each spring, leading pharmaceutical patent litigators for brand name and generic drug companies gather at the Paragraph IV Disputes conference to discuss, debate, and analyze the latest trends, judicial rulings and legislative developments affecting Hatch-Waxman litigation. As the industry prepares to address the fall out of global pharmaceutical patent losses of billions of dollars on the Hatch-Waxman landscape, the time for this conference has never been more relevant.
For more information, please click here.
Sign up for our newsletter and get the latest to your inbox.